Company profile: Medivation

1.1 - Company Overview

Medivation

Headquarter: United States

Founded: 20XX🔒

Employees: 100-500🔒

🌐 Website

Company description

Provider of biopharmaceutical R&D focused on rapid development of small‑molecule drugs to treat serious diseases with limited treatment options, including the development of MDV3100 for multiple stages of advanced prostate cancer in collaboration with Astellas Pharma.

Products and services

🔒

Key contacts

🔒

Financial details

🔒

1.2 - Competitors and similar companies to Medivation

Zymeworks

HQ: Canada Website

Description: Provider of computational biotechnology for optimizing therapeutic antibodies and other protein-based therapeutics, with a pipeline of bispecific antibodies and antibody-drug conjugates targeting HER2, folate receptor-α, mesothelin, glypican-3, and NaPi2b, including zanidatamab, zanidatamab zovodotin, ZW191, ZW171, ZW251, and ZW220.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Zymeworks company profile →

iOmx Therapeutics

HQ: Germany Website

Description: Provider of first-in-class cancer immunotherapies and discovery platforms targeting novel immune checkpoint modulators on tumor cells. Offerings include iOTargTM, a high-throughput genetic screening platform to identify checkpoint molecules; OMX-0407, an oral spectrum-selective SIK inhibitor in first-in-human trials; and IOMX-0675, a dual LILRB1/LILRB2 antibody to re-activate innate and adaptive immunity.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full iOmx Therapeutics company profile →

IN8bio

HQ: United States Website

Description: Provider of gamma-delta T cell immunotherapies for cancer, developing off-the-shelf and genetically modified approaches via its DeltEx platform. Pipeline includes INB-400 (Phase 2) for newly diagnosed glioblastoma using chemotherapy-resistant cells; INB-200 (Phase 1) for newly diagnosed glioblastoma; INB-100 (Phase 1) for leukemia patients undergoing hematopoietic bone marrow transplant; and DeltEx DRI for combination with chemotherapy.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full IN8bio company profile →

MediWise

HQ: United Kingdom Website

Description: Provider of medical research and development, pioneering cutting-edge wireless devices for medical diagnostics and monitoring.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full MediWise company profile →

Ayala Pharmaceuticals

HQ: United States Website

Description: Provider of clinical-stage small molecule therapeutics, including gamma secretase inhibitors that block Notch-pathway activation. Pipeline includes AL101 in Phase 2 for recurrent/metastatic adenoid cystic carcinoma and AL102 in Phase 2/3 for desmoid tumors, with a planned Phase 2 in relapsed/refractory T-cell acute lymphoblastic leukemia. Conducts clinical trials to evaluate safety and efficacy.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Ayala Pharmaceuticals company profile →

🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒

🔒 View all strategic buyers with complete profiles

Start Free Trial →

2.2 - Strategic buyer groups for Medivation

🔒

Buyer group 1: ████████ ████████

●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 2: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 3: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔓 Unlock all detailed buyer group breakdowns with complete company profiles

Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Medivation

Buyout Funds
50+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US buyout funds investing in Medivation's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe buyout funds in Medivation's sector and industry vertical
View Funds →

2.2 - Growth funds investing in similar companies to Medivation

Growth Equity Funds
40+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US growth equity funds investing in Medivation's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe growth equity funds investing in Medivation's sector and industry vertical
View Funds →

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Medivation

4.2 - Public trading comparable groups for Medivation

🔒

Comparable group 1: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 2: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 3: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Medivation

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA

🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Medivation

What does Medivation do?

Medivation is a provider of biopharmaceutical R&D focused on rapid development of small‑molecule drugs to treat serious diseases with limited treatment options, including the development of MDV3100 for multiple stages of advanced prostate cancer in collaboration with Astellas Pharma.

Who are Medivation's competitors?

Medivation's competitors and similar companies include Zymeworks, iOmx Therapeutics, IN8bio, MediWise, and Ayala Pharmaceuticals.

Where is Medivation headquartered?

Medivation is headquartered in United States.

How many employees does Medivation have?

Medivation has 1,000 employees 🔒.

When was Medivation founded?

Medivation was founded in 2010 🔒.

What sector and industry vertical is Medivation in?

Medivation is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Medivation

Who are the top strategic acquirers in Medivation's sector and industry

Top strategic M&A buyers and acquirers in Medivation's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Medivation?

Top strategic M&A buyers groups and sectors for Medivation include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Medivation's sector and industry vertical

Which are the top PE firms investing in Medivation's sector and industry vertical?

Top PE firms investing in Medivation's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Medivation's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Medivation's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Medivation's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Medivation include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Medivation's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Medivation?

The key public trading comparables and valuation benchmarks for Medivation include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Medivation for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Medivation with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Medivation's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Medivation with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Medivation's' sector and industry vertical?

Access recent funding rounds and capital raises in Medivation's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Medivation

Start Free Trial Book a Demo